Please use this identifier to cite or link to this item: https://hdl.handle.net/10321/5275
DC FieldValueLanguage
dc.contributor.authorBenjamin, Sherileneen_US
dc.contributor.authorAdam, Jamilaen_US
dc.contributor.authorKrishna, Suresh Babu Naiduen_US
dc.contributor.authorAssounga, Alain G.en_US
dc.date.accessioned2024-04-24T10:02:26Z-
dc.date.available2024-04-24T10:02:26Z-
dc.date.issued2020-
dc.identifier.citationBenjamin, S., Adam, J., Krishna, S.B.N. and Assounga, A.G. 2020. Antibodies to erythropoietin are associated with erythropoietin resistance in hemodialysis patients in KwaZulu-Natal (South Africa). Saudi Journal of Kidney Diseases and Transplantation. 31(5): 917-926. doi:10.4103/1319-2442.301198en_US
dc.identifier.issn1319-2442-
dc.identifier.issn2320-3838 (Online)-
dc.identifier.otherisidoc: PB7GW-
dc.identifier.otherpubmed: 33229756-
dc.identifier.urihttps://hdl.handle.net/10321/5275-
dc.description.abstractRecombinant human erythropoietin (rHuEPO) is a glycoprotein and biological equivalent to the endogenous compound administered to treat anemia of end-stage renal disease patients. Resistance to rHuEPO has been reported, whereby patients require higher and higher doses of rHuEPO to maintain an adequate hemoglobin level. In this study, assessment of native and administered erythropoietin (EPO), antibody and hemoglobin levels was carried out on a sample of patients with renal failure on hemodialysis (HD). This is a randomized controlled trial where consecutive subjects attending HD units at Addington Hospital and King Edward Hospital, Durban (South Africa) were included until the target number was reached. Forty patients with renal failure on HD and receiving recombinant EPO Beta (Recormon) for treatment of anemia via the subcutaneous route in weekly doses of 2000 IU, 4000 IU, 6000 IU, 8000 IU, 12,000 IU, or 18,000 IU according to the severity of the anemia were included after obtaining informed consent. Also included in the study were 10 HD patients not on rHuEPO therapy and 10 healthy individuals from the Durban University of Technology, recruited as described above to form the control group. ELISA was used to measure serum levels of EPO as well as antibodies to EPO. Results were analyzed by descriptive, inferential methods and by logistic regression analysis using IBM SPSS Statistics for Windows version 22.0. Antibodies to EPO were found in almost all patients who were receiving EPO. The highest levels of antibody to EPO were found to be associated with patients receiving the highest weekly dose of EPO (18,000 IU). Logistic regression analysis also revealed that serum levels of EPO, gender or age were not associated with any significant variation of serum antibody level. High levels of serum antibodies to EPO are a risk factor for EPO resistance.en_US
dc.format.extent10 pen_US
dc.format.mediumPrint-
dc.language.isoenen_US
dc.publisherMedknowen_US
dc.relation.ispartofSaudi Journal of Kidney Diseases and Transplantation; Vol. 31, Issue 5en_US
dc.subjectAntibodiesen_US
dc.subjectErythropoietinen_US
dc.subjectErythropoietin resistanceen_US
dc.subjectHemodialysisen_US
dc.subjectPatientsen_US
dc.subject.meshHumans-
dc.subject.meshKidney Failure, Chronic-
dc.subject.meshErythropoietin-
dc.subject.meshRecombinant Proteins-
dc.subject.meshAntibodies-
dc.subject.meshRenal Dialysis-
dc.subject.meshProspective Studies-
dc.subject.meshDrug Resistance-
dc.subject.meshMiddle Aged-
dc.subject.meshSouth Africa-
dc.subject.meshFemale-
dc.subject.meshMale-
dc.subject.meshAntibodies-
dc.subject.meshDrug Resistance-
dc.subject.meshErythropoietin-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshKidney Failure, Chronic-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshProspective Studies-
dc.subject.meshRecombinant Proteins-
dc.subject.meshRenal Dialysis-
dc.subject.meshSouth Africa-
dc.titleAntibodies to erythropoietin are associated with erythropoietin resistance in hemodialysis patients in KwaZulu-Natal (South Africa)en_US
dc.typeArticleen_US
dc.date.updated2024-04-19T13:34:42Z-
dc.publisher.urihttps://www.sjkdt.org/text.asp?2020/31/5/917/301198en_US
dc.identifier.doi10.4103/1319-2442.301198-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Research Publications (Applied Sciences)
Files in This Item:
File Description SizeFormat
Benjamin et al_2020.pdf183.43 kBAdobe PDFView/Open
Saudi Journal Copyright clearance.docxCopyright clearance150.14 kBMicrosoft Word XMLView/Open
Show simple item record

Page view(s)

62
checked on Jul 23, 2024

Download(s)

13
checked on Jul 23, 2024

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.